Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Wave Life Sciences (WVE) EBITDA (2016 - 2025)

Wave Life Sciences (WVE) has disclosed EBITDA for 11 consecutive years, with -$53.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 282.64% year-over-year to -$53.2 million, compared with a TTM value of -$204.4 million through Dec 2025, down 110.37%, and an annual FY2025 reading of -$204.4 million, down 110.37% over the prior year.
  • EBITDA was -$53.2 million for Q4 2025 at Wave Life Sciences, up from -$53.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $29.2 million in Q4 2024 and bottomed at -$61.7 million in Q3 2024.
  • Average EBITDA over 5 years is -$32.2 million, with a median of -$38.3 million recorded in 2021.
  • Peak annual rise in EBITDA hit 279.96% in 2024, while the deepest fall reached 954.02% in 2024.
  • Year by year, EBITDA stood at -$34.9 million in 2021, then decreased by 25.11% to -$43.6 million in 2022, then surged by 62.86% to -$16.2 million in 2023, then skyrocketed by 279.96% to $29.2 million in 2024, then tumbled by 282.64% to -$53.2 million in 2025.
  • Business Quant data shows EBITDA for WVE at -$53.2 million in Q4 2025, -$53.9 million in Q3 2025, and -$50.4 million in Q2 2025.